Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Prozac makers act over Chinese copy

Teresa Poole
Wednesday 24 June 1998 19:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

THERE IS a lot to be depressed about some days in China - as the inventors of the anti- depressant drug Prozac can confirm.

The American drug manufacturer Eli Lilly said yesterday that it will appeal to China's Supreme Court this month in a last attempt to win patent protection on the mainland for its best-selling Prozac.

Eli Lilly imports and sells about US$9m a year of Prozac in China.

Its problem is that at least two Chinese pharmaceutical companies are also manufacturing chemically identical copies of Prozac, after judgments by Chinese courts made it legal for anyone to produce the drug and sell it at a lower price.

Complaints by Western companies about intellectual property rights (IPR) infringements in China are nothing new.

IPR disputes have brought the US and China near to tit-for-tat trade wars several times in recent years, and the subject will be on President Clinton's agenda in trade negotiations during his summit visit.

Normally, the problem is straightforward pirating of copyright goods by Chinese companies, especially computer software, music CDs, CD-Roms, and more recently VCDs.

In these cases, Chinese factories are breaking the law by churning out pirated products which are protected under Chinese laws, but the laws are not implemented.

The US software industry this month said piracy-related losses in China more than doubled last year to US$1.4 billion, and estimated that 96 per cent of the computer software in use on the mainland was pirated.

The Prozac case is different, because it involves a product which Chinese courts have decided to allow mainland companies to copy, even though international patent agreements signed by Peking would seem to outlaw this.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in